Signal pathway profiling of prostate cancer using reverse phase protein arrays.
Reverse phase protein arrays represent a new proteomics microarray technology with which to study the fluctuating state of the proteome in minute quantities of cells. The activation status of cell signaling pathways controls cellular fate and deregulation of these pathways underpins carcinogenesis. Changes in pathway activation that occur between early stage prostatic epithelial lesions, prostatic stroma and the extracellular matrix can be analyzed by obtaining pure populations of cell types by laser capture microdissection (LCM) and analyzing the relative states of several key phosphorylation points within the cellular circuitry. We have applied reverse phase protein array technology to analyze the status of key points in cell signaling involved in pro-survival, mitogenic, apoptotic and growth regulation pathways in the progression from normal prostate epithelium to invasive prostate cancer. Using multiplexed reverse phase protein arrays coupled with LCM, the states of signaling changes during disease progression from prostate cancer study sets were analyzed. Focused analysis of phospho-specific endpoints revealed changes in cellular signaling events through disease progression and between patients. We have used a new protein array technology to study specific molecular pathways believed to be important in cell survival and progression from normal epithelium to invasive carcinoma directly from human tissue specimens. With the advent of molecular targeted therapeutics, the identification, characterization and monitoring of the signaling events within actual human biopsies will be critical for patient-tailored therapy.
Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Robert L
RL
Grubb
Valerie S
VS
Calvert
Julia D
JD
Wulkuhle
Cloud P
CP
Paweletz
W Marston
WM
Linehan
John L
JL
Phillips
Rodrigo
R
Chuaqui
Alfredo
A
Valasco
John
J
Gillespie
Michael
M
Emmert-Buck
Lance A
LA
Liotta
Emanuel F
EF
Petricoin
D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism*; D014408:Biomarkers, Tumor; D002471:Cell Transformation, Neoplastic / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008297:Male; D020928:Mitogen-Activated Protein Kinases; D010766:Phosphorylation; D011467:Prostate / Q000378:metabolism / Q000473:pathology*; D019048:Prostatic Intraepithelial Neoplasia / Q000378:metabolism / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D015398:Signal Transduction / Q000502:physiology*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D020928:Mitogen-Activated Protein Kinases